ALC-2203-AC

ALC-2203-AC is an investigational drug evaluated as an active comparator arm in a phase 2, randomized, double-blind, placebo- and active-controlled trial for the treatment of **acute bronchitis** in adults. The parent code ALC-2203 refers to a novel therapeutic, with the study aiming to find the optimal dose and safety in patients who present with bronchitis severity score criteria. ALC-2203-AC is specifically referenced as a comparator arm in the clinical trial protocol and is not currently associated with a publicly disclosed mechanism of action or precise molecular modality. The clinical trial excludes individuals with severe respiratory diseases such as asthma or chronic bronchitis, focusing on adults with recent symptom onset. The study is conducted at multiple centers in South Korea, including at least Konkuk University Medical Center, and includes 168 participants randomized across four arms—two with different doses of ALC-2203, one with ALC-2203-AC as an active comparator, and one with placebo. The trial assesses efficacy with the Bronchitis Severity Score (BSS), improvement in individual symptoms, and patient satisfaction scores.